MDM2 amplification is frequently observed in several cancer types, especially in tumors that still retain wild-type p53.216,217 Since MDM2-mediated ubiquitylation and degradation depend on its direct interaction with p53, researchers have been searching for small molecules that can inhibit this interaction to stabilize p53 and restore its activity. This evidence concerns the gene TP53 and cancer.